An approach to long-term sedative-hypnotic use

Nature and Science of Sleep

Volumn 4, Issue , 2012, Pages 53-61

  Shahid, Azmeh ^a   Chung, Sharon A ^a   Phillipson, Ron ^a   Shapiro, Colin M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Hypnotics; Insomnia; Long term use

Indexed keywords

EID: 84868153182     PISSN: None     EISSN: 11791608     Source Type: Journal    
DOI: 10.2147/NSS.S28362     Document Type: Review

References (84)

1. Wake up America: a national sleep alert: report of the National Commission on Sleep Disorders Research. Washington, DC: Department of Health and Human Services; National Commission on Sleep Disorders Research (US); 1993.
2. Montplaisir J, Hawa R, Moller H, et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol. 2003;18(1):29-38.
3. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates Arch Gen Psychiatry. 1985;42(3):225-232.
4. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989;262(11):1479- 1484.
5. Manabe K, Matsui T, Yamaya M, et al. Sleep patterns and mortality among elderly patients in a geriatric hospital. Gerontology. 2000; 46(6):318-322.
6. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Intern Med. 2002;251(3):207-216.
7. Leppavuori A, Pohjasvaara T, Vataja R, et al. Insomnia in ischemic stroke patients. Cerebrovas Dis. 2002;14(2):90-97.
8. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia. An overview. Pharmacoeconomics. 1996;10 Suppl 1:1-14.
9. No authors listed. Insomnia: assessment and management in primary care. National heart, lung, and blood institute working group on insomnia. Am Fam Physician. 1999;59(11):3029-3038.
10. Consensus conference. Drugs and insomnia. The use of medications to promote sleep. JAMA. 1984;251(18):2410-2414.
11. Czeisler CA, Richardson GS. Detection and assessment of insomnia. Clin Ther. 1991;13(6):663-679.
12. Trajanovic N, Radivojevic V, Kaushansky Y, Shapiro CM. Positive sleep state misperception - a new concept of sleep misperception. Sleep Med. 2007;8(2):111-118.
13. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavorial therapy versus zopiclone for the treatment of chronic primary insomnia in older patients. JAMA. 2006;295(24):2851-2858.
14. Lacks P, Morin C. Recent advances in the assessment and treatment of insomnia. J Consult Clin Psychol. 1992;6(4):586-594.
15. Morin C. Combined therapeutics for insomnia: should our first approach be behavioral or pharmacological? Sleep Med. 2006; 7(Suppl 1):S15-S19.
16. Morin AK. Strategies for treating chronic insomnia. Am J Manag Care. 2006;12(8 Suppl):S230-S245.
17. Edinger JD, Krystal AD. Sub typing primary insomnia: is sleep state misperception a distinct clinical entity? Sleep Med Rev. 2003; 7(3):203-214.
18. Riemann D. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010;14(1):19-31.
19. Kennedy S, Parikh SV, Shapiro CM. Defeating Depression. Thornhill, ON: Joli Joco Publications, Inc.; 1998.
20. Ohayon MM, Shapiro CM, Kennedy SH. Differentiating DSM-IV anxiety and depressive disorders in the general population: comorbidity and treatment consequences. Can J Psychiatry. 2000;45(2):166-172.
21. Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv. 2005;56(3):332-343.
22. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052-1060.
23. Shen J, Moller HJ, Wang X, et al. Mirtazapine a sedating antidepressant and improved driving safety in patients with major depressive disorder: a prospective randomized control trial of 28 patients. J Clin Psychiatry. 2009;70(3):370-377.
24. Levitan RD, Shen JH, Jinda RL, Driver HS, Kennedy SH, Shapiro CM. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. J Psychiatry Neurosci. 2000;25(4):337-346.
25. Anderson IM, Ferrier IN, Baldwin RC. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-396.
26. Benca RM. Consequences of insomnia and its therapies. J Clin Psychiatry. 2001;62 Suppl 10:33-38.
27. Kramer M. Hypnotic medication in the treatment of chronic insomnia: non nocere! Doesn't anyone care? Sleep Med Rev. 2000; 4(6):529-541.
28. McAndrews MP, Kayumov L, Phillipson R, Shapiro CM. Self-report of memory and affective dysfunction in association with medication use in a sample of individuals with chronic sleep disturbance. Hum Psychopharmacol. 2000;15(8):583-587.
29. McAndrews MP, Weiss RT, Sandor P, Taylor A, Carlen PL, Shapiro CM. Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacology. 2003;18(1):51-57.
30. Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology (Berl). 1986;88(4):426-433.
31. Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med. 1988;18(2):365-374.
32. Hanlon JT, Horner RD, Schmader KE, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther. 1998;64(6):684-692.
33. Adam K, Adamson L, Brezinova V, Hunter WM. Nitrazepam: lastingly effective but trouble on withdrawal. Br Med J. 1976;1(6025):1558-1560.
34. Oswald I, French C, Adam K, Gilham J. Benzodiazepine hypnotics remain effective for 24 weeks. Br Med J (Clin Res Ed). 1982;284(6319): 860-863.
35. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55(5):192-199.
36. Elie R, Ruther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel non benzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry. 1999;60(8):536-544.
37. Allen RP, Mendels J, Nevins DB, et al. Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months. J Clin Pharmacol. 1987;27(10):768-775.
38. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007;30(8):959-968.
39. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6(6):487-495.
40. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS. Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs. 1981;22(2):81-110.
41. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res. 1992;20(2):162-170.
42. Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med. 1996;100(3): 333-337.
43. Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med. 2005;6(2):107-113.
44. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double- blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793-799.
45. Jacobs GD. Is eszopiclone appropriate and effective for the long-term clinical management of insomnia. Sleep. 2004;27(2):345.
46. Morin CM, Bastien CH, Brink D, Brown TR. Adverse effects of temazepam in older adults with chronic insomnia. Hum Psychopharmacol. 2003;18(1):75-82.
47. Regestein QR, Reich P. A sleep clinic within a general hospital psychiatry service. Gen Hosp Psychiatry. 1980;2(2):112-117.
48. Gillin JC, Byerley WF. Drug therapy: the diagnosis and management of insomnia. N Engl J Med. 1990;322(4):239-248.
49. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drugs. 2003;26(4):261-282.
50. Shah R, Uren Z, Baker A, Majeed A. Deaths from antidepressants in England and Wales 1993-1997: analysis of a new national database. Psychol Med. 2001;31(7):1203-1210.
51. Bolster M, Curran J, Busuttil A. A five year review of fatal self-ingested overdoses involving amitriptyline in Edinburgh 1983-1987. Hum Exp Toxicol. 1994;13(1):29-31.
52. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ. 1995;310(6974):221-224.
53. Shapiro CM, Parry MR. Is unemployment a cause of Parasuicide. Br Med J (Clin Res Ed). 1984;289(6458):1622.
54. Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription hypnotics. Biol Psychiatry. 1998;43(9):687-693.
55. Kripke DF. Chronic hypnotic use: deadly risks, doubtful benefit. Sleep Med Rev. 2000;4(1):5-20.
56. Bliwise DL. Treating insomnia: pharmacological and tnonpharmacological approaches. J Psychoactive Drugs. 1991;23(4):335-341.
57. Shapiro CM, MacFarlane JG, MacLean AW. Alleviating sleep-related discontinuance symptoms associated with benzodiazepine withdrawal: a new approach. J Psychosom Res. 1993;37 Suppl 1:55-57.
58. Shapiro CM, Ohayon MM, Ebrahim I, Grunstein R. Fighting Fatigue and Sleepiness. Thornhill, ON: Joli Joco Publications, Inc.; 2005.
59. Hajak G, Geisler P. Experience with zolpidem 'as needed' in primary care settings. CNS Drugs. 2004;18 Suppl 1:35-40.
60. Vallieres A, Morin CM, Guay B, Bastien CH, LeBlanc M. Sequential treatment for chronic insomnia: a pilot study. Behav Sleep Med. 2004;2(2):94-112.
61. Morin CM. Cognitive-behavioral approaches to the treatment of insomnia. J Clin Psychiatry. 2004;65 Suppl 16:33-40.
62. Morin CM, Belanger L, Bastien C, Vallieres A. Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse. Behav Res Ther. 2005;43(1):1-14.
63. Morin CM, Vallieres, A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia. A randomized controlled trial. JAMA. 2009;301(19):2005-2015.
64. Shapiro CM, Sherman D, Peck DF. Withdrawal from benzodiazepines by initially switching to zopiclone. Eur Psychiatry. 1995;10(Suppl 3):145S-151S.
65. Shapiro C. Zopiclone as a catalyst to hypnotic withdrawal. In: Joyce D, Partinen M, Roth T, Ruther E, (Chairmen). Zopiclone: From Clinical Practice to Quality of Life. Copenhagen, Denmark: AEP; 1994:31.
66. Lemoine P, Ohayon MM. Is hypnotic withdrawal facilitated by the transitory use of a substitute drug? Prog Neuropsychopharmacol Biol Psychiatry. 1997;21(1):111-124.
67. Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep. 2005;28(4):499-521.
68. Hauri PJ, Olmstead EM. Reverse first night effect in insomnia. Sleep. 1989;12(2):97-105.
69. Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Testretest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res. 2002;53(3):737-740.
70. Chesson A Jr, Hartse K, Anderson WM, et al. Practice parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep. 2000;23(2):237-241.
71. Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003;26(3):342-392.
72. Morgenthaler T, Alessi C, Friedman L, et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep. 2007;30(4):519-529.
73. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens Insomnia Scale. J Psychosom Res. 2003;55(3):263-267.
74. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
75. Shapiro CM, Flanigan M, Fleming JA, et al. Development of an adjective checklist to measure five FACES of fatigue and sleepiness. Data from a national survey of insomniacs. J Psychosom Res. 2002;52(6): 467-473.
76. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-1123.
77. Léger D, Partinen M, Hirshkowitz M, Chokroverty S, Hedner J; EQUINOX (Evaluation of daytime QUality Impairment by Nocturnal awakenings in Outpatient's eXperience) Survey Investigators. Characteristics of insomnia in a primary care setting: EQUINOX survey of 5293 insomniacs from 10 countries. Sleep Med. 2010;11(10): 987-998.
78. Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified release formulations into primary care. J Clin Psychiatry. 2007;9(1):25-31.
79. Roehrs T, Roth T. 'Hypnotic' prescription patterns in a large managed- care population. Sleep Med. 2004;5(5):463-466.
80. Virk S, Schwartz TL, Jindal S, Nihalani N, Jones N. Psychiatric medication induced obesity: an aetiologic review. Obes Rev. 2004; 5(3):167-170.
81. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004;164(3):327-332.
82. Biswas PN, Wilton LV, Shakir SA. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. J Psychopharmacol. 2003;17(1):121-126.
83. Luby ED, Singareddy RK. Long-term therapy with lithium in a private practice clinic: a naturalistic study. Bipolar Disord. 2003;5(1): 62-68.
84. National Institutes of Health. National Institute of Health Sate of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep. 2005;28(9):1049-1057.